A Metabolite Specific 3D Stack-of-Spiral bSSFP Sequence for Improved
  Lactate Imaging in Hyperpolarized [1-$^{13}$C]Pyruvate Studies on a 3T
  Clinical Scanner by Tang, Shuyu et al.
A Metabolite Specific 3D Stack-of-Spiral bSSFP
Sequence for Improved Lactate Imaging in
Hyperpolarized [1-13C]Pyruvate Studies on a 3T Clinical
Scanner
Shuyu Tang1,2, Robert Bok2, Hecong Qin1,2, Galen Reed3, Mark VanCriekinge2, Romelyn
Delos Santos2, William Overall2, Juan Santos2, Jeremy Gordon2,
Zhen Jane Wang 1,2, Daniel B. Vigneron1,2, Peder E.Z. Larson1,2
1UC Berkeley-UCSF Graduate Program in Bioengineering, University of California, San
Francisco and University of California, Berkeley
2Department of Radiology and Biomedical Imaging, University of California - San Francisco,
San Francisco, California.
3HeartVista, Los Altos, California, USA
Address correspondence to:
Shuyu Tang
Byers Hall, Room 102
1700 4th St
San Francisco, CA 94158
E-MAIL: shuyu.tang@ucsf.edu
Approximate Word Count: 200 (abstract) 4692 (body)
Submitted Sep 1, 2019, to Magnetic Resonance in Medicine as a Full Paper.
ar
X
iv
:2
00
8.
08
80
0v
1 
 [p
hy
sic
s.m
ed
-p
h]
  2
0 A
ug
 20
20
Abstract
Purpose: The balanced steady-state free precession sequence has been previously explored
to improve the efficient use of non-recoverable hyperpolarized 13C magnetization, but suffers
from poor spectral selectivity and long acquisition time. The purpose of this study was to
develop a novel metabolite-specific 3D bSSFP ("MS-3DSSFP") sequence with stack-of-spiral
readouts for improved lactate imaging in hyperpolarized [1-13C]pyruvate studies on a clinical
3T scanner.
Methods: Simulations were performed to evaluate the spectral response of the MS-3DSSFP
sequence. Thermal 13C phantom experiments were performed to validate the MS-3DSSFP
sequence. In vivo hyperpolarized [1-13C]pyruvate studies were performed to compare the
MS-3DSSFP sequence with metabolite specific gradient echo ("MS-GRE") sequences for
lactate imaging.
Results: Simulations, phantom and in vivo studies demonstrate that the MS-3DSSFP se-
quence achieved spectrally selective excitation on lactate while minimally perturbing other
metabolites. Compared with MS-GRE sequences, the MS-3DSSFP sequence showed approx-
imately a 2.5-fold SNR improvement for lactate imaging in rat kidneys, prostate tumors in
a mouse model and human kidneys.
Conclusions: Improved lactate imaging using the MS-3DSSFP sequence in hyperpolarized [1-
13C]pyruvate studies was demonstrated in animals and humans. The MS-3DSSFP sequence
could be applied for other clinical applications such as in the brain or adapted for imaging
other metabolites such as pyruvate and bicarbonate.
Key words: bSSFP, 13C, Hyperpolarized, MRI, metabolic imaging, Pyruvate,
Lactate
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Introduction
Magnetic resonance imaging with hyperpolarized 13C-labeled compounds via dynamic nu-
clear polarization (DNP) has been used to non-invasively study metabolic processes in
vivo (1, 2). This method provides a transient signal enhancement of more than 10,000
fold compared to imaging 13C compounds at thermal equilibrium. However, as soon as the
pre-polarized 13C-labeled compound leaves the polarizer, its hyperpolarized state irreversibly
decay to the thermal equilibrium with a decay constant characterized by T1, which is typ-
ically less than one minute. Therefore, imaging approaches with fast readouts and efficient
use of hyperpolarized magnetization are favorable.
Hyperpolarized [1-13C]pyruvate has been widely used to monitor metabolic pathways in a
number of applications (3–8) and its feasibility for clinical applications has been demon-
strated (9–12). The MR signals of the hyperpolarized [1-13C]pyruvate (173 ppm) and its
downstream metabolites - [1-13C]lactate (185 ppm), [1-13C]pyruvate hydrate (181 ppm),
[1-13C]bicarbonate (163 ppm) and [1-13C]alanine (178 ppm) - are typically acquired using
gradient echo ("GRE") sequences (CSI (2, 13), multi-echo IDEAL (14, 15), metabolite spe-
cific EPI (16, 17) or spiral (18) acquisition) where the transverse magnetization is spoiled
at the end of each repetition time. Compared to GRE acquisitions, the balanced steady
state free precession ("bSSFP") (19–25) sequence can acquire the nonrenewable hyperpo-
larized magnetization more efficiently by repetitively refocusing transverse spins, which is
especially valuable for imaging metabolites with long T2s (23,26) such as [1-13C]pyruvate or
[1-13C]lactate.
Our work focuses on improving lactate imaging with hyperpolarized [1-13C]pyruvate injec-
tions using a bSSFP framework. Three bSSFP strategies for lactate imaging have been pro-
posed in the prior works. The first strategy (20) utilized a broadband pulse to excite all com-
ponents (i.e. pyruvate, lactate, bicarbonate, alanine, pyruvate-hydrate) in [1-13C]pyruvate
studies and decomposed the spectral information using multi-echo readouts. By acquiring
2
all compounds at one time, this strategy limits the acquisition optimization (e.g. flip angle,
resolution) for individual metabolites and would require a longer acquisition time if not all
the compounds in the spectrum are of interest.
The second strategy (24) reduced the number of excited compounds - only excited lactate,
pyruvate hydrate and alanine - and applied a saturation pulse to suppress undesired signals
from alanine and pyruvate hydrate at the beginning of each bSSFP acquisition. There are
three main drawbacks in this strategy. Since the conversion between pyruvate hydrate and
pyruvate maintains an equilibrium in the liquid state (27, 28), the pre-saturated pyruvate
hydrate signal may recover and still contaminate lactate acquisitions at later bSSFP echoes.
Directly saturating pyruvate hydrate would also accelerate the loss of pyruvate magnetization
and reduce the signals of downstream metabolites. In addition, the saturation performance
may be imperfect in the regions where transmit B1 profile is not homogeneous.
The third strategy (25) excited one metabolite at a time (i.e. metabolite specific excitation)
without a suppression pulse and was applied for imaging [1-13C]urea, [1-13C]pyruvate and
[1-13C]lactate with the bSSFP sequence on a 14.1T scanner. To meet the constraint of
short TR in bSSFP sequence, this strategy designed a multiband RF pulse using a convex
optimization approach (29). Compared with single-band RF pulses, multiband RF pulses
could potentially shorten the RF duration by releasing the constraints on frequency ranges
of no interest. Our work adapted this strategy to a clinical 3T scanner.
This article presents a novel metabolite specific 3D bSSFP sequence ("MS-3DSSFP") with
stack-of-spiral readouts for improved dynamic lactate imaging in hyperpolarized [1-13C]pyruvate
studies on a clinical 3T scanner. A lactate specific excitation pulse was developed using a
previously described approach (29) and stack-of-spiral readouts were used to accelerate the
acquisition. The excitation profile of the newly designed RF pulse at the bSSFP state was
simulated to investigate the banding artifacts and to examine the spectral selectivity of the
RF pulse. Thermally polarized 13C phantom experiments were performed to validate the
MS-3DSSFP sequence. In vivo hyperpolarized [1-13C]pyruvate experiments were performed
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on healthy rats, prostate cancer mouse model and patients with renal tumors to compare the
MS-3DSSFP sequence with metabolite specific GRE ("MS-GRE") sequences, in the aspects
of signal-to-noise ratio (SNR), image artifacts and impact on other metabolites.
Methods
Sequence design and simulation
The MS-3DSSFP sequence (Figure 1) consists of a multiband RF pulse and a center-out 3D
uniform-density stack-of-spiral readout. The RF pulse was designed using a prior approach
(29) to minimize the pulse duration. This pulse had a duration of 9ms, a maximum B1 of
0.2195G, a 40Hz passband on lactate (0Hz), a 40Hz stopband with 5% ripples on pyruvate
hydrate (-128Hz) and 40Hz stopbands with 0.5% ripples on bicarbonate (-717Hz), pyruvate
(-395Hz) and alanine (-210Hz). The 3D stack-of-spiral trajectory consists of 16 stacks and
each stack consists of four 3.8ms interleaves. All gradients have zero net area over the course
of one repetition. A 6 pulse non-linear ramp preparation scheme (i.e. 4o, 16o, 24o, 36o,
48o, 60o for a flip angle of 60o) was used to achieve a stable frequency response while the
reverse-ordered pulses were used for tip back. The MS-3DSSFP sequence was implemented
on a GE Signa MR 3T scanner (GE Healthcare, Waukesha, WI) using a commercial software
(RTHawk, HeartVista, Los Altos, CA).
In the bSSFP sequence, TR determines the frequency locations of banding artifacts. A TR
of 15.3ms was used for the MS-3DSSFP sequence to maximize the distance between banding
artifacts and metabolite frequencies. The excitation profiles of the RF pulse and its averaged
transverse magnetization over all echoes of bSSFP acquisitions were simulated. Simulation
parameters are: number of RF pulses = 50, TR = 15.3ms, T1 = 30s, T2 = 1s, 6 non-linear
ramp preparation pulses, flip angle = 60o.
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The choice of flip angle for the bSSFP sequence in the hyperpolarized study is a tradeoff
between banding artifacts and preserving magnetization for dynamic imaging. Prior bSSFP
work (22) has shown a favorable use of large flip angle (>100o) to reduce banding artifacts.
However, to perform dynamic imaging in hyperpolarized studies, a small flip angle around
30o in MS-GRE acquisitions (30) (equivalent to 60o in the bSSFP sequence) was required to
maintain sufficient SNR for multiple time points. In our work, we used a flip angle of 60o to
achieve a compromise between the two considerations.
Phantom and Animal Experiments
To test the MS-3DSSFP sequence, phantom experiments were performed on a 13C-enriched
sodium bicarbonate syringe phantom (T1 ≈ 26s, T2 ≈ 1.5s) with a dual-tuned 1H/13C
transceiver birdcage coil. 3D images of the phantom were acquired along with proton images
and field maps. To test the excitation profile, 13C images were acquired with a center
frequency offset, both at excitation and at acquisition, by 0Hz, 128Hz, 210Hz, 395Hz, and
717 Hz relative to the phantom frequency, to mimic the images of lactate, pyruvate hydrate,
alanine, pyruvate and bicarbonate, respectively. At the frequency of each metabolite, 13C
images were also acquired with small frequency offsets from -30 to 30 Hz with a step of 10Hz.
Acquired data were always demodulated to the phantom frequency so that reconstructed
images wouldn’t be blurred due to off-resonance reconstruction.
Hyperpolarized [1-13C]pyruvate animal experiments were performed on healthy Sprague-
Dawley rats (N = 3) and transgenic adenocarcinoma of mouse prostate (TRAMP) mice (N
= 3) to test our MS-3DSSFP sequence in vivo. 13C/1H birdcage coils (8cm diameter for
rats, 5cm diameter for mice) were used. All animal studies were conducted under protocols
approved by the University of California San Francisco Institutional Animal Care and Use
Committee (IACUC). Both rats and mice were anesthetized with isoflurane (1-2%) delivered
via oxygen gas at 1L/min and placed in a supine position on a heated pad throughout the
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duration of the experiments. [1-13C]pyruvic acid (Sigma Aldrich, St. Louis, MO) mixed
with 15mM trityl radical (GE Healthcare, Waukesha, WI) and 1.5mM Gd-DOTA (Guerbet,
Roissy, France) was polarized in a 3.35T SPINlab polarizer (GE Healthcare, Waukesha, WI)
at 0.8K for ∼1h, resulting in a 80mM [1-13C]pyruvate solution, with final pH of 6-8. The
hyperpolarized [1-13C]pyruvate was injected into the animal via tail vein catheters, ∼3mL
for each rat and ∼350µL for each mouse.
Hyperpolarized 13C sequence parameters for animal experiments are shown in Table 1. Each
animal received two identical injections of same dose of [1-13C]pyruvate. Lactate signals were
acquired using the MS-3DSSFP sequence in one injection ("experiment A") but using a 3D
MS-GRE sequence (described below) in the other injection ("experiment B"). Pyruvate
and alanine signals were acquired using the same 3D MS-GRE sequence in both injections.
Such experiment design that different acquisitions were used for lactate while same MS-
GRE acquisitions were used for pyruvate and alanine, allows comparing the MS-3DSSFP
sequence with a MS-GRE sequence for lactate imaging, as well as examining the perturbation
of the MS-3DSSFP sequence on pyruvate and alanine signals. Bicarbonate signals were not
acquired due to its inherently low signals and would not provide sufficient signals to compare
between the two sequences. Flip angles shown in Table 1 were chosen based on previous
studies (31). A flip angle of 20o was large enough to see pyruvate signals at a reasonable
spatial resolution. A flip angle of 30o for lactate and alanine imaging aimed to maintain
sufficient SNR for multiple time points. From preclinical results, we found alanine signals
were generally low in the kidneys. Therefore, we chose to use a flip angle of 90o in clinical
studies to make sure we can see alanine signals at first couple of time points, although it was
not good for acquiring signals over multiple time points.
The 3DMS-GRE sequence consists of a single-band spectral-spatial excitation (130Hz FWHM
passband, 870Hz stopband) (32) and stack-of-spiral readouts. Each stack was a 22ms single-
shot spiral readout. The two injections shared the same spatial resolution, temporal reso-
lution and number of time points. The 3D MS-GRE sequence used 16 excitations for a 3D
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encoding and each excitation pulse used a flip angle of 7.67o so that the equivalent flip angle
of these 16 excitations was the same as a 60o flip angle used in the MS-3DSSFP sequence.
The effective flip angle θeq of N excitations with a flip angle of θ for each excitation is cal-
culated as arccos(cos(θ)N). Initial pre-scan frequency and power calibration were performed
on a 13C urea phantom which was removed before pyruvate injection. All acquisitions were
started 6s after the end of pyruvate injection. For each experiment, a 13C frequency spectrum
was acquired and real-time 13C B1 calibration (33) was performed right before metabolite
acquisition.
For rat experiments, an anatomical localizer was acquired using proton 3D bSSFP sequence
(FOV 16 × 16 × 17.92cm, Matrix size 256 × 256 × 112). For the TRAMP mice experiment,
an anatomical localizer was acquired using proton T2-weighted fast spin echo sequence (FOV
6 × 6cm, Matrix size 512 × 512). For all animal experiments, a B0 map was acquired using
IDEAL IQ sequence (FOV 32 × 32cm, Matrix size 256 × 256).
Human study
Hyperpolarized [1-13C]pyruvate human studies (N = 2) were performed to demonstrate the
feasibility of applying the MS-3DSSFP sequence (Figure 1) in the clinical setting. Patients
with renal tumors that required surgical removal were recruited under a UCSF institutional
review board approved protocol and provided with written informed consent for participation
in the study. An Investigational New Drug approval was obtained from the U.S. Food and
Drug Administration for generating the agent and implementing the clinical protocol. 1.47g
of Good Manufacturing Practices (GMP) [1-13C]pyruvate (Sigma Aldrich, St. Louis, MO)
mixed with 15mM electron paramagnetic agent (EPA) (AH111501, GE Healthcare, Oslo,
Norway) was polarized using a 5T SPINlab polarizer (General Electric, Niskayuna, NY)
before being rapidly dissolved with 130oC water and forced through a filter that removed
EPA. The solution was then collected in a receiver vessel and neutralized with NaOH and Tris
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buffer. The receive assembly that accommodates quality-control processes provided rapid
measurements of pH, pyruvate and EPA concentrations, polarization, and temperature. In
parallel, the hyperpolarized solution was pulled into a syringe (Medrad Inc, Warrendale, PA)
through a 0.2µm sterile filter (ZenPure, Manassas, VA) and transported into the scanner for
injection. The integrity of this filter was tested in agreement with manufacturer specifications
prior to injection. A 0.43mL/kg dose of ∼250mM pyruvate was injected at a rate of 5mL/s
via an intra-venous catheter placed in the antecubital vein, followed by a 20mL saline flush.
In human studies, 13C kidney images were acquired with in-house built clamshell transmit
coil and 8-channel paddle receive array (34). 13C sequence parameters for this study are
presented in Table 1. Similar as the experiment design in animal experiments, the patient
received two injections to compare the MS-3DSSFP sequence with MS-GRE sequences. The
MS-GRE sequence used in this study was a multi-slice 2D MS-GRE sequence with the
same excitation pulse and the same single-shot spiral readout as used in the animal studies.
13C dynamic imaging was started 6s after the bolus arrival in kidney which was monitored
by a bolus tracking sequence (33). Initial pre-scan frequency and power calibration were
performed on 13C urea phantom attached outside the receive coil, which was removed before
pyruvate injection. Real-time 13C frequency and power calibration (33) were performed on
the renal tumor and triggered upon bolus arrival. Proton anatomical reference was acquired
with a 4 channel paddle receive coil, using a 2D SSFSE sequence with FOV 38 × 38cm,
matrix size 512 × 512.
Reconstruction and Data Analysis
For all studies, gridding of k-space data were performed using Kaiser-Bessel gridding method
(35) (http://web.stanford.edu/class/ee369c/mfiles/gridkb.m) with an oversampling factor of
1.4 and a kernel width of 4.5. The gridded k-space data was then inverse Fourier transformed
to the reconstructed image. Multi-channel data were combined by using pyruvate signals as
8
coil sensitivity maps (36). For display purposes, images were zero-filled by a factor of 2 and
applied with a 2D fermi filter.
Area-under-the-curve (AUC) images were calculated by summing the complex data through
time. Signal-to-noise ratio (SNR) was calculated as signal magnitude divided by the standard
deviation of the real part of the noise. Lactate-to-pyruvate AUC ratio images were calculated
by dividing the SNR of lactate AUC images by the SNR of pyruvate AUC images. To compare
AUC of a metabolite between experiment A (pyruvate and alanine: MS-GRE; lactate: MS-
3DSSFP) and experiment B (pyruvate, lactate, and alanine: MS-GRE) (Table 1), SNR of the
AUC images was calculated and then divided by the SNR of pyruvate AUC images acquired
in the same experiment. To compare dynamic curves of a metabolite between experiment A
and experiment B, SNR of each time point was calculated and then divided by the highest
SNR of the pyruvate dynamic curve acquired in the same experiment.
Signal levels of undesired metabolites in MS-3DSSFP lactate acquisitions were estimated.
First, the concentration ratio between an undesired metabolite and lactate was estimated
using the signals acquired from experiment B where all compounds were acquired with MS-
GRE sequences. Flip angle was compensated in the concentration ratio. Next, to estimate
the signal ratio between an undesired metabolite and lactate in MS-3DSSFP, the concen-
tration ratio was multiplied with MS-3DSSFP point spread function (PSF) amplitude ratio
between the undesired metabolite and lactate. The MS-3DSSFP PSF amplitude was cal-
culated by multiplying MS-3DSSFP excitation profile with the simulated PSF amplitude of
the MS-3DSSFP readout. The following equation describes the above calculation:
px =
Sx ∗ sin(θl) ∗ δx ∗ Ix
Sl ∗ sin(θx) [1]
where p is the signal level (%) of an undesired metabolite x in MS-3DSSFP lactate ac-
quisitions, l is lactate, S is the signal measured in experiment B, θ is the flip angle used
in experiment B, δ is the stopband amplitude of the excitation RF pulse used in the MS-
3DSSFP sequence, I is the central amplitude of the simulated off-resonance PSF of the
interleaved spiral readouts used in the MS-3DSSFP sequence. Pyruvate hydrate signals were
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assumed to be as 8% of pyruvate signals (2). Stopband amplitudes δ are described in pulse
design: 0.5% for alanine, 0.5% for pyruvate and 5% for pyruvate hydrate. The off-resonance
PSF amplitudes I of the MS-3DSSFP readouts are obtained from simulations (Supporting
Information Figure S1): 0.327 for alanine, 0.191 for pyruvate and 0.701 for pyruvate hydrate.
Results
Simulated excitation profiles of the MS-3DSSFP sequence and its averaged transverse mag-
netization over all bSSFP echoes are shown in Figure 2. Frequency bands and stopband
ripples of the excitation profiles were as desired. Most banding artifacts fell outside of the
desired frequency bands except one banding artifact which was observed 18Hz upfield from
the alanine frequency. In the simulation, the amplitude of this banding artifact was about a
third of the on-resonance peak, although its actual value in a hyperpolarized 13C pyruvate
study depends on the T1 and T2 of alanine as well as the conversion rate between pyruvate
and alanine.
Results of validating the MS-3DSSFP sequence on a [13C]bicarbonate syringe phantom (T1
∼= 26s, T2 ∼= 1.5s) with a rat birdcage coil are shown in Figure 3. 13C images, proton
images and B0 maps scaled to 13C frequency were provided. The dash-line-boxed slice shows
a bright proton image but a dark 13C image. This is consistent with the large B0 variation (-
50Hz) at that slice. Results of validating the excitation profile of the bSSFP sequence on the
phantom are presented in Supporting Information Figure S2. Excitation profiles measured
from phantom experiments were found to be consistent with the simulation.
Results of representative hyperpolarized [1-13C]pyruvate experiments to compare the MS-
3DSSFP sequence with MS-GRE sequences using the experiment parameters in Table 1 are
presented in Figure 4 (rat), Figure 5 (TRAMP mouse) and Figure 6 (renal tumor patient).
Comparing lactate AUC maps of the two experiments, no banding artifacts were observed in
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the MS-3DSSFP results. This finding agrees with the homogenous B0 maps found in most
areas of rat kidneys, TRAMP tumors and human kidneys, although large B0 variations are
found near the tissue-air interface. In some tumor regions, lactate-to-pyruvate AUC ratio
maps reveal different contrasts between the two experiments, as shown in Figure 5 and Figure
6. Compared to results of experiment B (pyruvate: MS-GRE; lactate: MS-GRE), lactate-to-
pyruvate AUC ratio map of experiment A (pyruvate: MS-GRE; lactate: MS-3DSSFP) shows
better alignment with the underlying T2 weighted proton images. This could be a result
of T2 contrast provided by the MS-3DSSFP sequence. Higher values of lactate-to-pyruvate
AUC ratio map are found in experiment A compared to experiment B, demonstrating the
MS-3DSSFP sequence provides higher SNR over MS-GRE sequences. AUC maps of pyruvate
and alanine show consistent contrast between the two experiments, demonstrating minimal
perturbation of the newly designed RF pulse on pyruvate and alanine.
Representative dynamic curves of lactate, pyruvate and alanine signals are presented in
Figure 7 acquired with experiment parameters described in Table 1. Metabolites signal
ratios between the two experiments are presented in Figure 8. Compared with MS-GRE
sequences, the MS-3DSSFP sequence shows an overall approximately 2.5X SNR improvement
and demonstrates higher SNR performance at every time point for lactate imaging in rat
kidneys, tumors of TRAMP mice and human kidneys. Comparing AUC between the two
experiments, there is almost no difference in pyruvate and a 5% to 20% difference in alanine
AUC, which demonstrates the lactate spectral selectivity of the MS-3DSSFP sequence.
Signal levels of undesired metabolites (i.e. pyruvate and alanine) in MS-3DSSFP lactate
acquisitions were quantified in three types of ROIs: rat kidneys, tumors of TRAMP mice
and human kidneys (Table 2). The highest signal contribution from undesired metabolites
was found in rat kidneys - 0.07% from alanine, 1.24% from pyruvate and 3.64% from pyruvate
hydrate, where 1% means that the ratio between the undesired metabolite and lactate is 1%.
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Discussion
Metabolite Specific Excitation for bSSFP
We designed a multiband RF pulse (Figure 1) under the constraint of short TR in a bSSFP
sequence to achieve spectrally selective excitation on lactate while minimally perturbing other
metabolites on a clinical 3T scanner. The 9ms pulse duration was primarily determined by
the frequency difference between lactate and pyruvate hydrate (128Hz at 3T) which has the
closest frequency to lactate among all compounds in hyperpolarized [1-13C]pyruvate studies.
The newly designed RF pulse had a maximum power of 0.2195G and did not experience
specific absorption rates (SAR) issues in our studies.
Our MS-3DSSFP sequence can be easily adapted to image [1-13C]pyruvate or [1-13C]bicarbonate.
Because these two metabolites have larger frequency differences from other compounds com-
pared to the frequency difference of lactate to pyruvate hydrate, it is guaranteed to find a
solution of metabolite specific excitation pulse for these two metabolites while meeting the
TR requirement in our studies. In contrast, it is challenging to design a metabolite specific
excitation pulse for imaging alanine, which has a frequency difference of 82Hz (at 3T) to
pyruvate hydrate, much closer than the frequency difference between lactate to pyruvate
hydrate.
Spiral bSSFP vs Cartessian bSSFP
Spiral readouts were used in the MS-3DSSFP to accelerate the acquisition. All prior HP
13C bSSFP work used Cartesian readouts, which brought challenges to acquire multiple
metabolites in dynamic imaging. For example, whole human brain HP 13C imaging typically
uses a matrix size of 16 × 16 × 16 and a FOV of 24 × 24 × 24 cm. Assuming a TR of 15ms,
3D Cartesian readouts need 16 × 16 × 15ms = 3.84s to cover a volume for one metabolite,
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which would result in insufficient temporal resolution when more than one metabolite needs
to be acquired. Given the relatively small matrix size, undersampling strategies will only
achieve limited acceleration, therefore fast imaging readouts are preferred (37). Under the
same requirement of matrix size and FOV, stack-of-spiral readouts using two interleaves per
stack could achieve an acquisition time of 2 × 16 × 15ms = 0.48ms and an even larger matrix
size (24 x 24 x 24), assuming a 3.8ms readout time for each spiral interleaf (same as what we
used in this study), a 5 G/cm maximum gradient and a 20 G/cm/ms maximum slew rate.
The center k-space of the spiral readout is not at the center of the TR, which may cause
a slight SNR loss compared to Cartesian readouts. Assuming a spiral readout duration of
3.8 ms as used in our studies and a T2∗ of 50 ms, SNR loss of using spiral readouts will be
1-exp(-1.9/50) = 4%.
MS-3DSSFP vs MS-GRE
By comparing the results of two experiments whose experiment parameters are shown in
Table 1 (experiment A: MS-3DSSFP for lactate, MS-GRE for pyruvate and alanine; ex-
periment B: MS-GRE for lactate, pyruvate and alanine.), we assess the performance of the
MS-3DSSFP sequence in the aspects of SNR, contrast, banding artifacts, artifacts by excit-
ing undesired metabolites and impact on acquisition of other metabolites. These issues will
be discussed in the following paragraphs.
To fairly compare SNR between the MS-3DSSFP sequence and MS-GRE sequences, we used
the same spatial resolution, starting time of acquisition, temporal resolution and number of
time points. The effective flip angle (see definition in Methods) of the MS-GRE sequence was
the same as the flip angle used in the MS-3DSSFP sequence. Readout durations of the two
sequences were not matched since T2∗ limits the readout duration of a MS-GRE sequence.
Compared with MS-GRE sequences, our MS-3DSSFP sequence has shown an overall 2.5-fold
SNR improvement (Figure 7 and Figure 8) for dynamic lactate imaging in hyperpolarized
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[1-13C]pyruvate studies. The SNR improvement ratio would increase with T2 (Supporting
Information Figure S3). Besides utilizing T2, other features of the MS-3DSSFP sequence
could also contribute to the SNR improvement, including shorter echo time due to shorter
RF pulse and shorter spiral readout time which results in less signal reduction caused by B0
inhomogeneity.
Compared with MS-GRE sequences, the MS-3DSSFP sequence can also provide T2 contrast
for tissue characterization. In our studies, such contrast differences are potentially observed
in some tumor regions in lactate-to-pyruvate AUC ratio maps as shown in Figure 5 and
Figure 6.Parameters of the MS-3DSSFP sequence (e.g. flip angle, TR) could be explored to
enable jointly estimating lactate T2 and pyruvate-to-lactate conversion rate.
Excitation profiles of a bSSFP sequence are determined by both the excitation profile of the
RF pulse and banding artifacts governed by the chosen TR. Two types of image artifacts
could be a result of excitation profiles of a bSSFP sequence: null-signal banding artifacts of
metabolites of interest and artifacts by exciting undesired metabolites. Comparing in vivo
lactate AUC results (Figure 4, Figure 5, Figure 6) of MS-GRE and MS-3DSSFP, no null-
signal banding artifacts are found in the MS-3DSSFP results. In some peripheral regions
of TRAMP tumors (Figure 5) where large B0 variations are noted, both MS-GRE and MS-
3DSSFP sequences shows hypointense signals in AUC maps of pyruvate and lactate but show
hyperintense signals in pyruvate-to-lactate AUC ratio maps. This indicates that both MS-
GRE and MS-3DSSFP sequences are sensitive to B0 inhomogeneity for different reasons.For
MS-3DSSFP, the reason is reduced excitation due to a narrow excitation bandwidth (40Hz).
For MS-GRE, reduced excitation could also be a reason although not as worse as MS-
3DSSFP, and another reason could be reduced signal due to long spiral readouts (22ms),
which can be improved by using proper off-resonance correction (38,39).
Exciting undesired metabolites would cause both artificially elevated lactate signals and
ring-shaped artifacts. Simulation (Supporting Information Figure S1) shows that for the
interleaved spiral readouts used in our studies, artifacts from pyruvate hydrate and alanine
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mostly stay in the center of the point spread function while artifacts from pyruvate, urea and
bicarbonate are spread out, which will cause ring-shaped artifacts. No ring-shaped artifacts
are observed in the MS-3DSSFP images. Signal levels of undesired metabolites (i.e. pyruvate
and alanine) in MS-3DSSFP lactate acquisitions were summarized in Table 2. These signal
levels could be higher if acquisition starts early when pyruvate and pyruvate hydrate signals
are high while lactate signals are yet to build up.
Exciting undesired metabolites would also sacrifice their magnetization and reduce their
signals. Comparing AUC results between the two experiments (Figure 8), there is almost
no difference in pyruvate and a 5% to 20% difference in alanine AUC. The cost in alanine
signals is consistent with the simulation (Figure 2) and phantom (Supporting Information
Figure S2) results where a banding artifact is identified 18Hz upfield from alanine frequency.
Therefore, it is more robust to apply our MS-3DSSFP sequence for imaging ROIs with low
alanine productions such as most tumors, kidney or brain.
Interleaving Different Sequences In One Injection
In hyperpolarized 13C studies, signals of different metabolites are usually acquired using the
same sequence so that results reveal the contrast of metabolite concentration. In our studies,
we developed a method of imaging different metabolites using different sequences in one
injection, i.e., imaging lactate using MS-3DSSFP while imaging pyruvate and alanine using
MS-GRE. This method is achieved by using a commercial software (RTHawk, HeartVista,
Los Altos, CA) where interleaving different sequences are easily incorporated. It could
potentially provide multiple contrasts for multiple metabolites in a single injection, whereas
the same purpose could possibly be achieved by using a MR-Fingerprinting type of acquisition
(40).
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Precautions of Performing MS-3DSSFP Experiments
To run the MS-3DSSFP sequence, several issues need to be carefully handled. As discussed
before, the RF pulse used in the MS-3DSSFP sequence has a narrow bandwidth (40Hz) and
real-time frequency calibration (33) is crucial to the robustness of this sequence. Further-
more, the multiband RF pulse used in this study does not avoid exciting urea, therefore, it
is suggested to remove the urea phantom which was used in pre-scan frequency and power
calibration prior to pyruvate injection, otherwise there could be spiral off-resonance artifacts
from urea signals. Finally, the multiband RF pulse was not slice-selective, therefore the field
of view along the slice direction needs to be as large as the extent of 13C receive coils.
Conclusion
This work describes a novel 3D bSSFP sequence that integrates a lactate specific excitation
pulse and stack-of-spiral readouts for improved lactate dynamic imaging in hyperpolarized
[1-13C]pyruvate studies on a clinical 3T scanner. Compared with MS-GRE sequences, the
MS-3DSSFP sequence showed an overall 2.5X SNR improvement for lactate imaging in rat
kidneys, tumors of TRAMP mice and human kidneys. Future work will include exploring
joint estimation of lactate T2 and pyruvate-to-lactate conversion rate, extending the ap-
plications of the proposed sequence for imaging regions with acceptable B0 homogeneity
such as human brain, as well as imaging other metabolites (e.g. pyruvate, bicarbonate) in
hyperpolarized [1-13C]pyruvate studies.
Acknowledgements
The authors thank Lucas Carvajal, Jennifer Chow, Hsin-yu Chen, Justin Delos Santos, James
Slater, Namasvi Jariwala, Mary Mcpolin, Kimberly Okamoto for their help on the project.
16
This work was supported by the National Institute of Biomedical Imaging and Bioengineering
(P41EB013598, R01EB016741, U01EB026412), the American Cancer Society (RSG-18-005-
01-CCE), and a UCSF Research Evaluation and Allocation Committee Shared Instrument
Award.
17
List of Figures
1 Pulse sequence of the proposed MS-3DSSFP acquisition (a). It consists of a
lactate specific excitation pulse and a 3D center-out stack of spiral readout (c).
Each stack (b) consists of four interleaves. The details of the excitation pulse
are described in Figure 2. Lighted shaded regions refer to the data acquisition
window. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2 Simulated excitation profiles of the excitation pulse alone (blue) and its aver-
aged transverse magnetization over 64 pulses of a bSSFP acquisition (red). An
overall view of the profile is shown in graph (a) and graph (b). Zoomed views
(±40Hz) of excitation profiles around each metabolite are shown in graph (c)
and graph (d). The excitation pulse has a 40Hz passband on lactate (0Hz),
a 40Hz stopband of 5% maximum ripple on pyruvate hydrate (-128Hz) and
40Hz stopbands of 0.5% maximum ripples on bicarbonate (-717Hz), pyruvate
(-395Hz) and alanine (-210Hz). Simulation parameters for bSSFP acquisi-
tions include: number of RF pulses = 64, TR = 15.3ms, T1 = 30s, T2 = 1s,
6 non-linear ramp preparation pulses, flip angle = 60o . . . . . . . . . . . . 31
3 Validation of the MS-3DSSFP sequence on a [13C]bicarbonate syringe phan-
tom (T1 ∼= 26s, T2 ∼= 1.5s) with a rat birdcage coil. 13C images were
acquired at 8 × 8 × 20mm and reconstructed at 4 × 4 × 20mm. Bright
spots at the bottom of proton images are the water pad in the coil. B0 maps
are shown at 13C frequency. The dash-line-boxed slice shows a bright proton
image but a dark 13C image, consistent with the large B0 variation (-50Hz)
at that slice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
18
4 Comparison of the MS-3DSSFP sequence with a 3D MS-GRE sequence on a
healthy rat with hyperpolarized [1-13C]pyruvate injections using experiment
A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP) and experiment
B (pyruvate, lactate and alanine: MS-GRE). Experiment parameters are de-
scribed in Table 1. AUC maps of each metabolite are displayed at the max-
imum signal across slices. B0 maps were thresholded using a mask removing
the pixels with SNR lower than 3 in the water magnitude images. B0 maps
colorbar is displayed at the bottom. Lactate-to-pyruvate AUC ratio maps of
the kidney slices are shown and thresholded using a mask removing the pixels
with SNR lower than 3 in the lactate or pyruvate magnitude image. . . . . 33
5 Comparison of the MS-3DSSFP sequence with a 3D MS-GRE sequence on a
TRAMP mouse prostate tumor with hyperpolarized [1-13C]pyruvate injections
using experiment A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP)
and experiment B (pyruvate, lactate and alanine: MS-GRE). Experiment
parameters are described in Table 1. AUC images of each metabolite, and
lactate-to-pyruvate AUC ratio images and B0 maps are shown. B0 and AUC
ratio maps are thresholded the same way as described in Figure 4. B0 maps
colorbar is displayed at the bottom. . . . . . . . . . . . . . . . . . . . . . . 34
6 Comparison of the MS-3DSSFP sequence with a multi-slice 2D MS-GRE se-
quence in the kidneys of a patient with a renal tumor with hyperpolarized
[1-13C]pyruvate injections using experiment A (pyruvate and alanine: MS-
GRE; lactate: MS-3DSSFP) and experiment B (pyruvate, lactate and alanine:
MS-GRE). Experiment parameters are described in Table 1. AUC images of
each metabolite, and lactate-to-pyruvate AUC ratio images and B0 maps are
shown. B0 and AUC ratio maps are thresholded the same way as described
in Figure 4. B0 maps colorbar is displayed at the bottom. . . . . . . . . . . 35
19
7 Representative dynamic curves of lactate, pyruvate and alanine signals ac-
quired in experiment A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP)
and experiment B (pyruvate, lactate and alanine: MS-GRE). Experiment pa-
rameters are described in Table 1. All signals were divided by corresponding
noise signals and then divided by the highest value of the pyruvate dynamic
curve. Corresponding dynamic images are shown in Supporting Information
Figure S4, Supporting Information Figure S5 and Supporting Information
Figure S6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
8 Metabolites AUC ratios and lactate ratios of dynamic curves between exper-
iment A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP) and exper-
iment B (pyruvate, lactate and alanine: MS-GRE) at each time point. Ex-
periment parameters are described in Table 1. Data of rat kidneys, TRAMP
tumors and human kidneys were included in the summary with a criterion of
SNR greater than 3. The averaged lactate ratios are shown by the solid lines
and ±1 standard deviations are shown by the dashed lines. . . . . . . . . . 37
20
List of Tables
1 13C sequence parameters used in rat, TRAMP and human studies with hy-
perpolarized [1-13C]pyruvate injection. For the same subject, two experiments
(A and B) would be performed back-to-back for comparison. In experiment
A, lactate signals were acquired with the metabolite specific 3D SSFP (MS-
3DSSFP) sequence while pyruvate and alanine signals were acquired with the
metabolite specific GRE (MS-GRE) sequences. In experiment B, all three
metabolites were acquired with MS-GRE sequences. In TRAMP mouse stud-
ies and one of the human study, experiment B was performed first. In other
studies, experiment A was performed first. . . . . . . . . . . . . . . . . . . . 38
2 Estimated signal levels of off-resonance metabolites in lactate acquisitions
using the MS-3DSSFP sequence. Signal levels are estimated according to Eq.
1. A signal level of 1% means that in a MS-3DSSFP lactate acquisition, the
ratio between the off-resonance metabolite and lactate is 1%. . . . . . . . . 39
21
Supporting Information
S1 Simulations of off-resonance PSF of the interleaved spiral readouts (4 interleaves, 3.8ms
for each interleaf) used in this study. Frequencies of metabolites are Lactate = 0Hz,
Pyruvate Hydrate = -128Hz, Alanine = -210Hz, Pyruvate = -395Hz, Urea = -635Hz,
Bicarbonate = -717Hz.
S2 Validation of the MS-3DSSFP sequence on a 13C-enriched sodium bicarbonate phantom
(T1 = 26s, T2 = 1.5s). 13C images were acquired with a center frequency offset, both
at excitation and at acquisition, by 0Hz, 128Hz, 210Hz, 395Hz, and 717 Hz relative
to the phantom frequency, to mimic the images of lactate ("Lac"), pyruvate hydrate
("Pyrh"), alanine ("Ala"), pyruvate ("Pyr") and bicarbonate ("Bic"), respectively. At
the frequency of each metabolite, 13C images were also acquired with small frequency
offsets from -30 to 30 Hz with a step of 10Hz. Acquired data were always demodulated
to the phantom frequency so that reconstructed images wouldn’t be affected by blurring
artifacts due to off-resonance reconstruction. All 13C images were acquired at 8 × 8
× 20mm and reconstructed at 4 × 4 × 20mm. The mean value of the phantom area
for each image is normalized by the value of the lactate image at zero frequency offset
and plotted in graph (b). Simulation results from Figure 2 are also displayed here for
comparison.
S3 Simulation of bSSFP SNR as a function of T2, normalized to SNR is 1 when T2 is 1s.
Simulation parameters include T1 = 30s, TR 15.3ms, # of time points 30, # of RF
pulses 64.
S4 Dynamic images and ROI signal curves of a rat kidney slice of the experiments de-
scribed in Figure 4. Each image is displayed to its own maximum signal to visualize
metabolites at all time points. All ROI signals were divided by corresponding noise
signals and then divided by the highest value of the pyruvate dynamic curve.
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S5 Dynamic images and ROI signal curves of a TRAMP mouse tumor slice of the exper-
iments described in Figure 5. Each image is displayed to its own maximum signal to
visualize metabolites at all time points. All ROI signals were divided by corresponding
noise signals and then divided by the highest value of the pyruvate dynamic curve.
S6 Dynamic images and ROI signal curves of a human renal tumor slice of the experiments
described in Figure 6. Each image is displayed to its own maximum signal to visualize
metabolites at all time points. All ROI signals were divided by corresponding noise
signals and then divided by the highest value of the pyruvate dynamic curve.
S7 13C images of Supporting Figure S2 were displayed without applying demodulation,
meaning reconstruction frequency was the same as excitation frequency. This is how
reconstruction was performed in all in vivo experiments - reconstruction was always
performed at the lactate frequency. This figure validates the combined effects of exci-
tation profiles and blurring artifacts caused by spiral readouts.
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Figure 1: Pulse sequence of the proposed MS-3DSSFP acquisition (a). It consists of a
lactate specific excitation pulse and a 3D center-out stack of spiral readout (c). Each stack
(b) consists of four interleaves. The details of the excitation pulse are described in Figure 2.
Lighted shaded regions refer to the data acquisition window.
30
Figure 2: Simulated excitation profiles of the excitation pulse alone (blue) and its averaged
transverse magnetization over 64 pulses of a bSSFP acquisition (red). An overall view of the
profile is shown in graph (a) and graph (b). Zoomed views (±40Hz) of excitation profiles
around each metabolite are shown in graph (c) and graph (d). The excitation pulse has
a 40Hz passband on lactate (0Hz), a 40Hz stopband of 5% maximum ripple on pyruvate
hydrate (-128Hz) and 40Hz stopbands of 0.5% maximum ripples on bicarbonate (-717Hz),
pyruvate (-395Hz) and alanine (-210Hz). Simulation parameters for bSSFP acquisitions
include: number of RF pulses = 64, TR = 15.3ms, T1 = 30s, T2 = 1s, 6 non-linear ramp
preparation pulses, flip angle = 60o
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Figure 3: Validation of the MS-3DSSFP sequence on a [13C]bicarbonate syringe phantom
(T1 ∼= 26s, T2 ∼= 1.5s) with a rat birdcage coil. 13C images were acquired at 8 × 8 ×
20mm and reconstructed at 4 × 4 × 20mm. Bright spots at the bottom of proton images are
the water pad in the coil. B0 maps are shown at 13C frequency. The dash-line-boxed slice
shows a bright proton image but a dark 13C image, consistent with the large B0 variation
(-50Hz) at that slice.
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Figure 4: Comparison of the MS-3DSSFP sequence with a 3D MS-GRE sequence on a
healthy rat with hyperpolarized [1-13C]pyruvate injections using experiment A (pyruvate
and alanine: MS-GRE; lactate: MS-3DSSFP) and experiment B (pyruvate, lactate and
alanine: MS-GRE). Experiment parameters are described in Table 1. AUC maps of each
metabolite are displayed at the maximum signal across slices. B0 maps were thresholded
using a mask removing the pixels with SNR lower than 3 in the water magnitude images.
B0 maps colorbar is displayed at the bottom. Lactate-to-pyruvate AUC ratio maps of the
kidney slices are shown and thresholded using a mask removing the pixels with SNR lower
than 3 in the lactate or pyruvate magnitude image.
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Figure 5: Comparison of the MS-3DSSFP sequence with a 3D MS-GRE sequence on a
TRAMP mouse prostate tumor with hyperpolarized [1-13C]pyruvate injections using experi-
ment A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP) and experiment B (pyruvate,
lactate and alanine: MS-GRE). Experiment parameters are described in Table 1. AUC im-
ages of each metabolite, and lactate-to-pyruvate AUC ratio images and B0 maps are shown.
B0 and AUC ratio maps are thresholded the same way as described in Figure 4. B0 maps
colorbar is displayed at the bottom.
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Figure 6: Comparison of the MS-3DSSFP sequence with a multi-slice 2D MS-GRE sequence
in the kidneys of a patient with a renal tumor with hyperpolarized [1-13C]pyruvate injections
using experiment A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP) and experiment
B (pyruvate, lactate and alanine: MS-GRE). Experiment parameters are described in Table
1. AUC images of each metabolite, and lactate-to-pyruvate AUC ratio images and B0 maps
are shown. B0 and AUC ratio maps are thresholded the same way as described in Figure 4.
B0 maps colorbar is displayed at the bottom.
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Figure 7: Representative dynamic curves of lactate, pyruvate and alanine signals acquired
in experiment A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP) and experiment B
(pyruvate, lactate and alanine: MS-GRE). Experiment parameters are described in Table 1.
All signals were divided by corresponding noise signals and then divided by the highest value
of the pyruvate dynamic curve. Corresponding dynamic images are shown in Supporting
Information Figure S4, Supporting Information Figure S5 and Supporting Information Figure
S6.
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Figure 8: Metabolites AUC ratios and lactate ratios of dynamic curves between experiment
A (pyruvate and alanine: MS-GRE; lactate: MS-3DSSFP) and experiment B (pyruvate,
lactate and alanine: MS-GRE) at each time point. Experiment parameters are described
in Table 1. Data of rat kidneys, TRAMP tumors and human kidneys were included in the
summary with a criterion of SNR greater than 3. The averaged lactate ratios are shown by
the solid lines and ±1 standard deviations are shown by the dashed lines.
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Table 1: 13C sequence parameters used in rat, TRAMP and human studies with hyperpolar-
ized [1-13C]pyruvate injection. For the same subject, two experiments (A and B) would be
performed back-to-back for comparison. In experiment A, lactate signals were acquired with
the metabolite specific 3D SSFP (MS-3DSSFP) sequence while pyruvate and alanine signals
were acquired with the metabolite specific GRE (MS-GRE) sequences. In experiment B, all
three metabolites were acquired with MS-GRE sequences. In TRAMP mouse studies and
one of the human study, experiment B was performed first. In other studies, experiment A
was performed first.
38
Table 2: Estimated signal levels of off-resonance metabolites in lactate acquisitions using
the MS-3DSSFP sequence. Signal levels are estimated according to Eq. 1. A signal level
of 1% means that in a MS-3DSSFP lactate acquisition, the ratio between the off-resonance
metabolite and lactate is 1%.
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Supporting Information Figure S1: Simulations of off-resonance PSF of the inter-
leaved spiral readouts (4 interleaves, 3.8ms for each interleaf) used in this study.
Frequencies of metabolites are Lactate = 0Hz, Pyruvate Hydrate = -128Hz, Alanine
= -210Hz, Pyruvate = -395Hz, Urea = -635Hz, Bicarbonate = -717Hz.
2
Supporting Information Figure S2: Validation of the MS-3DSSFP sequence on a
13C-enriched sodium bicarbonate phantom (T1 ∼= 26s, T2 ∼= 1.5s). 13C images
were acquired with a center frequency offset, both at excitation and at acquisition,
by 0Hz, 128Hz, 210Hz, 395Hz, and 717 Hz relative to the phantom frequency, to
mimic the images of lactate (”Lac”), pyruvate hydrate (”Pyrh”), alanine (”Ala”),
pyruvate (”Pyr”) and bicarbonate (”Bic”), respectively. At the frequency of each
metabolite, 13C images were also acquired with small frequency offsets from -30 to
30 Hz with a step of 10Hz. Acquired data were always demodulated to the phantom
frequency so that reconstructed images wouldn’t be affected by blurring artifacts due
to off-resonance reconstruction. All 13C images were acquired at 8 × 8 × 20mm and
reconstructed at 4 × 4 × 20mm. The mean value of the phantom area for each image
is normalized by the value of the lactate image at zero frequency offset and plotted in
graph (b). Simulation results from Figure 2 are also displayed here for comparison.
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Supporting Information Figure S3: Simulation of bSSFP SNR as a function of T2,
normalized to SNR is 1 when T2 is 1s. Simulation parameters include T1 = 30s, TR
15.3ms, # of time points 30, # of RF pulses 64.
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Supporting Information Figure S4: Dynamic images and ROI signal curves of a rat
kidney slice of the experiments described in Figure 4. Each image is displayed to its
own maximum signal to visualize metabolites at all time points. All ROI signals were
divided by corresponding noise signals and then divided by the highest value of the
pyruvate dynamic curve.
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Supporting Information Figure S5: Dynamic images and ROI signal curves of a
TRAMP mouse tumor slice of the experiments described in Figure 5. Each image
is displayed to its own maximum signal to visualize metabolites at all time points.
All ROI signals were divided by corresponding noise signals and then divided by the
highest value of the pyruvate dynamic curve.
6
Supporting Information Figure S6: Dynamic images and ROI signal curves of a
human renal tumor slice of the experiments described in Figure 6. Each image is
displayed to its own maximum signal to visualize metabolites at all time points. All
ROI signals were divided by corresponding noise signals and then divided by the
highest value of the pyruvate dynamic curve.
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Supporting Information Figure S7: 13C images of Supporting Figure S2 were dis-
played without applying demodulation, meaning reconstruction frequency was the
same as excitation frequency. This is how reconstruction was performed in all in vivo
experiments - reconstruction was always performed at the lactate frequency. This fig-
ure validates the combined effects of excitation profiles and blurring artifacts caused
by spiral readouts.
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